Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.48 |
| ▸ | CDC7 | O00311 | 5/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 10/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911794 | 0.77 | GSK3B (0.56) | GSK3BCDC7DBF4CDK2ALDH1A1 | |
| SCHEMBL25236233 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL29176245 | 0.70 | MAPT (0.48) | GSK3BCDC7DBF4CDK2PDE3B | |
| SCHEMBL23263983 | 0.70 | GSK3B (0.43) | GSK3BCDC7DBF4CDK2PDE3B | |
| SCHEMBL14911423 | 0.68 | KDM4E (0.42) | GSK3BCDK2PDE3BPDE3AKDM4E | |
| SCHEMBL26325418 | 0.67 | MAPT (0.50) | GSK3BCDC7DBF4CDK2PDE3B | |
| SCHEMBL31227630 | 0.65 | CYP2A6 (0.51) | CDC7DBF4 | |
| SCHEMBL31227321 | 0.65 | CYP2A6 (0.51) | GSK3BCDC7DBF4CDK2ROCK1 | |
| SCHEMBL11973132 | 0.65 | CA2 (0.46) | GSK3BCDC7DBF4ROCK1KDM4E | |
| SCHEMBL3977831 | 0.65 | GSK3B (0.52) | GSK3BCDC7DBF4CDK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | disclosed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | GSK3B 125/4885CDC7 2298/4885DBF4 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.